Effective New Weight-Loss Drugs Spur Jenny Craig Stock Plunge
The Bank of England left interest rates unchanged in a surprise move that mimicked the ’s pause on Wednesday. Continue reading this article with a Barron’s subscription SUBSCRIBE NOWBiotech and Pharma Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means...
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale shift of injectable drugs that treat obesity, investors may be pondering which pharmaceutical giant ...
Historically, weight-loss drugs have been highly touted and equally miserable failures (think Fen-phen, meridian, ephedra, to name a few). Demand is understandable; hundreds of millions of overweight people are hungry for something that can help them lose weight and keep it off. To wit, analy...
Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs are no longer on its list of drugs in short supply.
These comments also sparked a decline in shares ofNovo Nordisk(NYSE:NVO) stock. Novo Nordisk has developed multiple weight-loss drugs. Amgen Raises Expectations for Weight-Loss Drug Discussinginterim datafrom a Phase 2 trial of the company’s weight-loss drug, Amgen CEO Robert Bradway said “...
A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs. Roundhill Investments'GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leadersEli LillyandNovo Nordiskwith players developing new tr...
Weight-loss drugs like Wegovy and Mounjaro are wildly popular and effective, but their long-term health impacts are still unknown.
Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs from Eli Lilly (LLY). Lillyannouncedthat it would be selling the two lowest doses of its popular injectable obesity drug Zepbound in single-use vials th...
Novo stock dipped 1.2% to 135.30 on Monday, falling back below the 50-day line within a consolidation. Viking Therapeutics stock tumbled 6.3%. Viking is developing its own obesity drugs. Drug giants Amgen (AMGN) and Roche (RHHBY), which also are working on weight-loss drugs, edged h...